Skip to main content
. Author manuscript; available in PMC: 2010 Mar 30.
Published in final edited form as: Nat Biotechnol. 2009 Aug 16;27(9):858–863. doi: 10.1038/nbt.1559

Figure 2.

Figure 2

Vimentin Methyl-BEAMing of plasma from colorectal cancer patients. (a) The number of methylated vimentin fragments in 2 ml plasma from normal, age and sex-matched control patients. (b) The number of methylated vimentin fragments in 2 ml plasma from colorectal cancer patients of various stages. (c) Receiver operating characteristic (ROC) curves based on the number of methylated vimentin fragments for the indicated classes of samples. (d) ROC curves based on CEA level for the indicated classes of samples. The dotted lines in (a) (b) (c) represent 1 methylated fragment per 2 ml plasma DNA. The doted line in (d) represents 5 ng/ml CEA level.